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Establishment of Efficacy and Safety Assessment of Human 
Adipose Tissue-Derived Mesenchymal Stem Cells (hATMSCs)  
in a Nude Rat Femoral Segmental Defect Model
Human adipose tissue-derived mesenchymal stem cell (hATMSC) have emerged as a 
potentially powerful tool for bone repair, but an appropriate evaluation system has not 
been established. The purpose of this study was to establish a preclinical assessment system 
to evaluate the efficacy and safety of cell therapies in a nude rat bone defect model. 
Segmental defects (5 mm) were created in the femoral diaphyses and transplanted with 
cell media (control), hydroxyapatite/tricalcium phosphate scaffolds (HA/TCP, Group I), 
hATMSCs (Group II), or three cell-loading density of hATMSC-loaded HA/TCP (Group III-V). 
Healing response was evaluated by serial radiography, micro-computed tomography and 
histology at 16 weeks. To address safety-concerns, we conducted a GLP-compliant toxicity 
study. Scanning electron microscopy studies showed that hATMSCs filled the pores/surfaces 
of scaffolds in a cell-loading density-dependent manner. We detected significant increases 
in bone formation in the hATMSC-loaded HA/TCP groups compared with other groups. The 
amount of new bone formation increased with increases in loaded cell number. In a 
toxicity study, no significant hATMSC-related changes were found in body weights, clinical 
signs, hematological/biochemical values, organ weights, or histopathological findings. In 
conclusion, hATMSCs loaded on HA/TCP enhance the repair of bone defects and was found 
to be safe under our preclinical efficacy/safety hybrid assessment system. 
Key Words: Safety; Efficacy; Human Adipose Tissue-Derived Mesenchymal Stem Cells; 
HA/TCP Scaffold; Bone Defect Model; Nude Rats
Hyung Jun Choi
1,2, Jong Min Kim
2, 
Euna Kwon
2, Jeong-Hwan Che
2, 
Jae-Il Lee
2, Seong-Ryul Cho
3, 
Sung Keun Kang
3, Jeong Chan Ra
3, 
and Byeong-Cheol Kang
1,2
1Graduate School of Immunology, Seoul National 
University College of Medicine, Seoul; 
2Department 
of Experimental Animal Research, Biomedical 
Research Institute, Seoul National University 
Hospital, Seoul; 
3Stem Cell Research Center, RNL 
Bio Co., Ltd., Seoul, Korea
Received: 6 September 2010
Accepted: 17 February 2011
Address for Correspondence:
Byeong-Cheol Kang, PhD 
Department of Experimental Animal Research, Biomedical 
Research Institute, Seoul National University Hospital, 101 
Daehak-ro, Jongno-gu, Seoul 110-744, Korea
Tel: +82.2-2072-0841, Fax: +82.2-741-7620
E-mail: bckang@snu.ac.kr 
This study was supported by a grant from the Korea Food and 
Drug Administration.
DOI: 10.3346/jkms.2011.26.4.482  •  J Korean Med Sci 2011; 26: 482-491
ORIGINAL ARTICLE
Cell Therapy & Organ Transplantation
INTRODUCTION
The treatment of bone defects remains a challenging problem in 
orthopedics. Previous studies of bone defect repair rely mainly 
on the use of fresh autograft bone, bone graft substitutes (1-3), 
or tissue-engineering techniques that incorporate appropriate 
implants seeded with cells demonstrating osteogenic potential 
(3, 4). Human adipose tissue-derived mesenchymal stem cells 
(hATMSCs) are attractive for tissue-engineering approaches to 
bone regeneration because they not only demonstrate excellent 
expansion properties and osteogenic regeneration potential, but 
also exhibit immunoprivileged or immunomodulatory proper-
ties. In addition, scaffolds are required for tissue-engineering 
applications to deliver cells and act as templates for tissue regen-
eration. Hydroxyapatite/tricalcium phosphate (HA/TCP) bioma-
terials can guide bone tissue growth, facilitate bone formation 
or consolidation, and serve clinically as bone substitutes (5, 6).
  Several studies have reported risks associated with the use of 
mesenchymal stem cells (MSCs). The tumorigenic potential of 
MSCs was reported in in vitro and in vivo experimental settings 
using long-term expanded cell populations (7-9). Tasso et al. 
(10) reported that MSCs induced permanent tumor transfor-
mation of adjacent cells when loaded onto bioscaffolds, thus 
creating tumor niches. For these reasons, preclinical safety test-
ing should be completed prior to the use of MSCs in clinical tri-
als. However, an appropriate system has not been established 
to evaluate the efficacy and toxicity of MSCs in the context of 
stem cell properties. Studies of cell transplantation therapies in 
animal models are often hampered by partial or complete re-
jection of grafts. To avoid these confounds, we used immuno-
deficient nude rats as a model for transplantation studies. 
  In this study, we aimed to establish the preclinical efficacy 
and safety of a hybrid assessment system for cell-based thera-
pies in a bone defect model using athymic nude rats by 1) deter-
mining the capacity of hATMSCs with HA/TCP scaffolds to heal 
segmental defects, 2) confirming whether hATMSCs exhibit any 
toxicity in vivo. Our results will contribute to the standardization 
and implementation of regulatory requirements for new cellu-
lar therapies in orthopedics.
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MATERIALS AND METHODS
Isolation and culture of hATMSCs 
Adipose tissues were obtained by simple liposuction from the 
abdominal subcutaneous fat of human donors. All donors pro-
vided informed consent, and the donor program was approved 
by the Institutional Review Board of Seoul National University 
(IRB No. H-0610-015-186). The subcutaneous adipose tissues 
were digested with collagenase I (1 mg/mL) under gentle agi- 
tation at 37°C for 1 hr. Next, the digested tissues were filtered 
through a 100 μm nylon sieve to remove cellular debris and cen-
trifuged at 1,500 rpm for 5 min. The pellet was resuspended in 
DMEM (Invitrogen, Carlsbad, CA, USA)-based media contain-
ing 0.2 mM ascorbic acid and 10% fetal bovine serum (FBS). The 
cell suspension was re-centrifuged at 1,500 rpm for 5 min. The 
supernatant was discarded and the cell pellet was collected. The 
cell fraction was cultured overnight at 37°C/5% CO2 in DMEM-
based media containing 0.2 mM ascorbic acid and 10% FBS. Cell 
adhesion was checked under an inverted microscope the next 
day. After 24 hr, non-adherent cells were removed and washed 
with phosphate-buffered saline (PBS). The cell medium was 
changed to Keratinocyte-SFM (Invitrogen)-based media con-
taining 0.2 mM ascorbic acid, 0.09 mM calcium, 5 ng/mL recom-
binant epidermal growth factor (rEGF) and 5% FBS. The cells 
were maintained for four or five days until the cells became con-
fluent, and considered at this point to represent passage 0. When 
the cells were 90% confluent, they were subculture-expanded 
in Keratinocyte-SFM-based media containing 0.2 mM ascorbic 
acid, 0.09 mM calcium, 5 ng/mL rEGF and 5% FBS until passage 
3. The immunophenotypes of MSCs were then analyzed using 
a FACS Calibur Flow Cytometer. Every MSC harvest resulted in 
a homogenous population of cells with high expression levels 
of CD73 and CD90 and without expression of CD31, CD34 and 
CD45. Cell viability evaluated by the trypan blue exclusion meth-
od before shipping was > 95%. No evidence of bacterial, fungal, 
or mycoplasmal contamination was observed in cells tested be-
fore shipping. The procedures for MSC preparation were per-
formed under good manufacturing practice (GMP) conditions 
(RNL BIO, Seoul, Korea). 
  To assess their MSC character, cells were tested in vitro for 
mesenchymal multipotency (osteogenic, chondrogenic, adipo-
genic, neurogenic and myogenic differentiation) before trans-
plantation using lineage-specific stimulation (data not shown).
Preparation of implants and scanning electron 
microscopy (SEM)
Porous hydroxyapatite/β-tricalcium phosphate (HA/TCP) ce-
ramic blocks (Zimmer, Warsaw, IN, USA), with macropore size 
of 300-600 μm for and micropore size of ≤ 10 μm, porosity of 60%-
70%, and Ca:P ratio of 1.6 were shaped into cylinders approxi-
mately 3 mm in diameter and 5 mm in length with a 1 mm wide 
central canal. The HA/TCP scaffolds were cleaned by sonication, 
rinsed in distilled water, and then sterilized by gamma radiation. 
In order to improve their cell-adherent properties, the scaffolds 
were coated with human fibronectin (100 μg/mL) prior to cell 
loading. MSC-loaded implants were prepared by incubating 
human fibronectin-coated HA/TCP scaffolds in a three density 
of 7.5 × (10
5 or 10
6 or 10
7) cells/mL suspension of hATMSCs. Two 
millimeters of cell suspension were added to a 7 mL Vacutainer 
tube containing the ceramic implants. All loaded carriers were 
subjected to a vacuum to allow penetration of the MSC suspen-
sion. They were then placed in an incubator at 37°C for 3 hr. The 
loaded carriers were re-fed with cell media overnight and trans-
ported to the operating room. Cell-free implants were prepared 
in a similar fashion by incubating fibronectin-coated scaffolds 
in a suspension devoid of cells. This procedure was similar to 
one that was described previously (11). 
  Cell attachment on the scaffold was confirmed by SEM as pre-
viously described (12). Before delivery, specimens of cell-free 
scaffolds and various densities of cell-loaded scaffolds were 
fixed in glutaraldehyde (24 hr), dehydrated in ethanol, coated 
with gold palladium and photographed by SEM.
Animal model and experimental design
All animal experiments were approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of the Clinical Research 
Institute at Seoul National University Hospital (an AAALAC ac-
credited facility), and followed National Research Council (NRC) 
guidelines for the care and use of laboratory animals (revised 
1996). The rat femoral segmental defect model described here 
is a modification of a previous model used extensively to study 
long bone repair (11, 13). Twelve-week old adult male athymic 
nude rats (Harlan, Indianapolis, IN, USA) were used for xeno-
transplantation experiments. A total of 60 rats were divided into 
six groups (Table 1). Critical-sized femoral bone defects 5 mm in 
length were created in the mid-portion of the femoral diaphysis 
in each rat. In control animals, the bone defects were left empty 
with cell media. In Group I, the defects were filled with HA/TCP 
scaffold without any MSCs. In Group II, the defects were filled 
with hATMSC suspension (cell-loading density: 7.5 × 10
7 cells/
mL) alone to evaluate the therapeutic capacities of MSCs with-
out scaffold. Cell-loaded scaffolds were used to study the effects 
Table 1. Experimental design
GROUP Test item Cell-loading density
Control
   I
   II
Cell media (empty)
HA/TCP 
hATMSCs
0 cells/mL
0 cells/mL
7.5 × 10
7 cells/mL
Study group
   III (Low)
   IV (Medium)
   V (High)
 
hATMSCs + HA/TCP 
hATMSCs + HA/TCP 
hATMSCs + HA/TCP 
 
7.5 × 10
5 cells/mL
7.5 × 10
6 cells/mL
7.5 × 10
7 cells/mL
HA/TCP, hydroxyapatite/tricalcium phosphate; hATMSCs, human adipose tissue-
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of initial cell-loading density on bone tissue formation. Three 
scaffolds were constructed with cell-loading concentrations of 
7.5 × 10
5 cells/mL (Group III), 7.5 × 10
6 cells/mL (Group IV), or 
7.5 × 10
7 cells/mL (Group V). 
Surgical implantation
Femoral segmental defect surgeries were performed as follows 
(Fig. 1). Briefly, rats were anesthesized with zoletil/xylazine and 
prepared aseptically. A longitudinal skin incision was made 
along the lateral surface of the femoral diaphysis and the over-
lying periosteum was resected from the defect area. A polyeth-
ylene fixation plate (4 × 4 × 23 mm) was secured to the antero-
lateral aspect of the femur by four 1.1-mm Kirschner wires and 
two 34G cerclage wires, and a 5 mm transverse segment of the 
central diaphysis was removed with an oscillating bone saw 
(Surgic-XT, NSK Nakanishi Inc., Tochigi-ken, Japan) under 0.9% 
normal saline irrigation. The defect was filled with implants that 
varied by experimental group (see “Animal model and experi-
mental design”, above). Implants were secured by placing two 
4-0 Vicryl (Ethicon, Somerville, NJ, USA) sutures around the 
scaffold and the fixation plate. The muscles were apposed, and 
the fascia and skin were closed in a routine layered fashion. The 
animals were allowed full activity in their cages postoperatively.
Efficacy assessment by radiographic analysis 
Postoperative radiographs verified implant placement and served 
as a baseline for radiographic evaluation. Serial radiographs 
were taken on the day of operation, and at postoperative 4, 8, 
12, and 16 weeks, using a high-resolution radiography system 
(Faxitron 43805N, Hewlett-Packard, McMinnville, OR, USA). 
The exposure conditions were 40 kV, 1.2 mAs and 6.3 ms. The 
percentage areas of the femoral segmental defect occupied by 
newly formed bone were scored as previously described (14). 
The area percentage of bone regeneration filling the segmental 
defect and porous materials were graded from 1 to 4 using radio-
graph. The grades were defined as: [1] < 25% space of -; [2] 25% 
to 50% space of - ; [3] 50% to 75% space of - ; [4] > 75% space of - 
segmental defect and/or porous materials filled with new bone. 
The means of the scores of each group were calculated and com-
pared.
Efficacy assessment by micro-computed tomography 
(micro-CT) imaging
The representative excised bone specimens were scanned with 
a Skyscan 1076 (Skyscan, Antwerpen, Belgium) for three-dimen-
sional visualization of new bone formation in the segmental 
defect. Briefly, the specimens were placed in the holder and the 
centers of the segmental defects were identified with the scout 
view window. Femoral defects were scanned using 89 kVp, 112 
ms integration time with 0.5 mm filter. 
Efficacy assessment by histology and histomorphometry 
Sixteen weeks after the surgery, the animals were sacrificed and 
each defect area was evaluated histologically. The femora were 
dissected and fixed in 10% neutral-buffered formalin, decalci-
fied (6.5% nitric acid), embedded in paraffin, and cut into 5-μm 
sections. Specimen histology was examined by hematoxylin and 
eosin (H&E) staining. Stained sections from each group were 
observed under a light microscope and were scanned using an 
attached digital camera and NIS-Elements system (Nikon, To-
kyo, Japan). The new bone formation, residual HA/TCP scaffold 
and connective tissue areas were determined and converted to 
a percentage of total area of the bone defect with Image Software 
(Leica Application Suite System, Wetzlar, Germany). 
Safety assessment 
We conducted a general toxicity study in accordance with good 
laboratory practices (GLP) and the OECD Guidelines for the 
Testing of Chemicals (TG409) with some modifications. During 
the postoperative period, we observed all animals for changes 
in behavior, general clinical signs, mortality, body weight, and 
food consumption. 
Safety assessment by hematological and biochemical 
analysis
At 16 weeks after the surgery, hematological analyses were per-
A
B
C F
Implants preparation 
(hATMSCs + HA/TCP scaffold)
Bone defect creation Suture
D
E
Test item injection 
(Control, Group II)
Test item implantation 
(Group I, III, IV, V)
Fig. 1. Procedures for surgical 
implantation in the femoral seg-
mental defect model from implant 
preparation to closure. (A, B) Pre-
paration of the hATMSC-loaded 
implants, (C) femoral segmental 
defects, (D, E) transplantation of 
test items into the defects, (F) clo-
sure. Choi HJ, et al.  •  Efficacy and Safety of hATMSCs in Bone Defects
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formed with an animal blood analyzer (MS 9-5: Melet Schloes- 
ing Laboratories, Osny, France), including red blood cell (RBC) 
count, mean corpuscular volume (MCV), hemoglobin (Hb), 
mean corpuscular hemoglobin (MCH), mean corpuscular he-
moglobin concentration (MCHC), white blood cell (WBC) count, 
differential WBC count, platelets (PLT), and hematocrit (HCT). 
Prothrombin time (PT) and activated partial thromboplastin 
time (APTT) were measured with plasma samples obtained after 
mixing sodium citrate and centrifuged at 3,000 rpm for 15 min 
using an automated coagulation analyzer (ACL-100, Lexington, 
MA, USA). Serum biochemistries were analyzed with an auto-
mated chemistry analyzer (Hitachi 7070, Hitachi Co. Ltd., Tokyo, 
Japan) for the following parameters: total protein (TP), albumin 
(ALB), A/G, glucose (GLU), cholesterol (CHOL), triglycerides 
(TG), total bilirubin (TBIL), urea nitrogen (BUN), creatinine (CRE), 
alanine aminotransferase (ALT), asparate aminotransferase 
(AST), alkaline phosphatase (ALP), chlorine (Cl), calcium (Ca), 
potassium (K), and phosphorus (P).
Safety assessment by urinalysis and ocular observations 
At sacrifice, we measured the following parameters with a urine 
analyzer (Miditron Junior II, Roche Diagnostics, Mannheim, 
Germany): specific gravity, pH, leukocytes, nitrite, protein, glu-
cose, ketones, urobilinogen, bilirubin, and urinary hemoglobin. 
At the same time points, a veterinarian performed the following 
ocular examinations: pupillary light reflex (PLR), blink reflex, 
anterior segment, transparent media, and fundus.
Safety assessment by necropsy, organ weights, and 
histopathology 
At the end of the study the animals were sacrificed by bloodlet-
ting under deep anesthesia. Organ weights of the heart, liver, 
lungs, spleen, kidneys, adrenal glands, testes, brain and pituitary 
gland were determined by necropsy. Histopathological exami-
nations were performed on the femoral segmental defect (trans-
plantation site), heart, aorta, lungs, trachea, thyroid, parathy-
roid and salivary glands, stomach, duodenum, jejunum, ileum, 
colon, adrenals, testes, epididymes, prostate, urinary bladder, 
skeletal muscles, sciatic nerves, skin, mammary glands, pitu-
itary, eyes, optic nerves, liver, spleen, pancreas, mesenteric lymph 
nodes, thymus, kidneys, spinal cord and brain. After fixation in 
10% neutral-buffered formalin, all tissues were processed in a 
routine manner, embedded in paraffin, sectioned, and stained 
with H&E for light microscopic evaluation.
Statistical analysis 
Data are presented as means ± SD One-way ANOVA, was per-
formed using SPSS 12.0K to detect and compare differences 
among groups. For data sets that failed normality or equal vari-
ance testing, we used a post hoc Tukey’s test or Dunnet’s meth-
od for subsequent pairwise comparisons. P values (P < 0.05) in-
dicated significant differences between the control group and 
treated groups.
 
Fig. 2. SEM observations of hATMSC-loaded HA/TCP scaffolds with different cell densities. (A-C) HA/TCP scaffold, (D-L) varying density of hATMSC-loaded HA/TCP (D-F, 7.5 × 
10
5 cells/mL; G-I, 7.5 × 10
6 cells/mL; J-L, 7.5 × 10
7 cells/mL). Arrow, attached cells.
A × 50
B × 300
C × 1,000
D × 50
E × 300
F × 1,000
G × 50
H × 300
I × 1,000
J × 50
K × 300
L × 1,000Choi HJ, et al.  •  Efficacy and Safety of hATMSCs in Bone Defects
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RESULTS  
Due to two anesthetic deaths, 58 of the original 60 animals were 
evaluated at follow-up. Among these animals, one nude rat each 
in Groups I and V showed clinical signs of ataxia and dysplasia 
of the femur according to serial radiograph (related to pin track 
infection). The samples from these animals were excluded from 
the efficacy study.
Efficacy assessed by SEM observations
Cell attachment on scaffolds was confirmed by SEM (Fig. 2). 
Scanning electron micrographs revealed the ultrastructural ar-
chitecture of the fibronectin-coated HA/TCP scaffolds. The 
pores and surfaces of HA/TCP scaffolds were filled with hATM-
SCs in a cell loading density-dependent manner. In low density 
cell-loaded scaffolds, the attached cells appeared spindle-like 
on the scaffold surface. In higher density cell-loaded scaffolds, 
numerous spherical and spindle cells were detected in the 
pores and on the surface.     
Efficacy assessed by radiographic evaluation
High-resolution Faxitron radiographs provided sufficient clarity 
and detail to detect subtle changes occurring within the implants 
and the surrounding host bone (Fig. 3). Defects of control (me-
dia) and Group II (hATMSCs alone) rats remained unhealed at 
16 weeks. Nonunion at the host bone-implant interfaces oc-
curred in Group I (HA/TCP scaffold alone), and the defect ar-
eas appeared granular and fractured. The HA/TCP scaffolds 
showed incomplete resorption within the 16-week follow-up 
period. Radiographs demonstrated substantially more bone in 
animals that received hATMSCs-loaded HA/TCP scaffolds than 
those that received cell-free HA/TCP scaffolds. Unions between 
implant and host bone were seen in Groups III, IV and V. The 
defects in these groups were bridged with radiopaque osteoid 
tissue that was more radiopaque at higher cell-loading densi-
ties. At 12 weeks, union was complete and additional bone was 
evident in the scaffolds. The scores for percentage areas of the 
femoral segmental defect occupied by newly formed bone were 
significantly higher in Group V than in the control group. These 
differences among the groups were first detected at 4 weeks af-
ter implantation and were maintained at 16 weeks after implan-
tation. These data suggest that segmental defects that were filled 
with hATMSC-loaded HA/TCP scaffolds exhibited new bone 
formation in a cell loading density-dependent manner.
Efficacy assessed by micro-CT imaging
The defects in each group were visualized by three-dimensional 
micro-CT imaging (Fig. 4). Defects treated with cell media (con-
trol) and hATMSCs alone (Group II) did not close. Defects filled 
with cell-free HA/TCP scaffolds showed minor bone formation 
and bridging, but union was not complete. Micro-CT images 
demonstrate substantially greater bone formation in animals 
that received hATMSC-loaded HA/TCP scaffolds than in those 
that received cell-free HA/TCP scaffolds. The newly formed bone 
was more evenly distributed across the gap in Groups III, IV 
and V than in controls or Groups I and II. 
Efficacy assessed by histological and histomorphometrical 
evaluation
Photomicrographs of representative sections of the implant 
groups at 16 weeks are shown in Fig. 5. In controls, most defects 
were filled with loose fibrous tissue and vessels. Small amounts 
of callus could be seen in the position on the plate. This pattern 
was also observed in defects treated with hATMSCs alone in 
Group II. In defects filled with HA/TCP alone, the tissues around 
the scaffolds were predominantly filled with fibrous tissue even 
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Fig. 3. Radiographs of bone defects treated with hATMSC-loaded HA/TCP scaffolds. (A) Serial radiographs at postoperative 0, 4, 8, 12, and 16 weeks. (B) The percentage areas 
occupied by newly formed bone were scored from 1 to 4 (*P < 0.05 compared with control).Choi HJ, et al.  •  Efficacy and Safety of hATMSCs in Bone Defects
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at 16 weeks and most scaffolds remained unabsorbed by 16 
weeks. Defects treated with hATMSC-loaded HA/TCP scaffolds 
in Groups III, IV and V mainly consisted of bone woven into the 
pores of scaffolds and around the scaffolds. As the amount of 
loaded cells increased from Groups III to V, more new bone for-
mation was observed and the HA/TCP scaffolds were better ab-
sorbed. These signs indicate new bone formation in a cell load-
ing density-dependent manner. These findings were consistent 
with the results of radiography and micro-CT examinations in 
these groups. In Group V, the highest density loaded group, large 
amounts of new bone and marrow were observed in the defects, 
whereas very little scaffold seemed to be buried in the newly 
formed osseous tissues. Filling of the pores with new bone and 
vasculature was evident in regions deeper within the HA/TCP. 
Despite xenogeneic hATMSC transplantation, no adverse host 
responses such as lymphocytic infiltration was detected. 
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Fig. 5. Histolgical and his-
tomorphometric analysis of 
bone defects treated with 
hATMSC-loaded HA/TCP 
scaffolds at 16 weeks after 
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Fig. 4. Micro-computed tomography of bone defects at 16 weeks after surgery. (A) Control, (B) Group I, (C) Group II, (D) Group III, (E) Group IV, and (F) Group V. The dotted box 
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Fig. 6. Body weight changes in nude rats treated with hATMSC-loaded HA/TCP sca-
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  Histomorphometric analyses revealed bone in the healed de-
fects of femora treated with low (7.5 × 10
5 cells/mL), middle (7.5 
× 10
6 cells/mL), and high (7.5 × 10
7 cells/mL) density hATMSC-
HA/TCP scaffolds. The percentages of newly-formed bone were 
56.87 ± 23.856 vs 80.72 ± 17.170 vs 89.07 ± 6.518, respectively, 
indicating patterns of bone formation that increased according 
to cell-loading density. The bone formation in Groups IV and V 
was significantly greater than the mean area of bone induced 
by cell-free HA/TCP scaffolds alone (40.36 ± 18.442), in controls 
that received only cell media (52.40 ± 17.600), or hATMSCs alone 
(58.92 ± 15.774). Whereas the residual percentage of HA/TCP 
scaffolds in Group I was 14.11 ± 7.891, residual percentages of 
scaffold in Groups III, IV and V were 13.28 ± 8.855, 11.12 ± 8.476, 
3.04 ± 3.397, respectively. Percentages of new bone formation 
and residual scaffold showed an inverse relationship. The per-
centages of connective tissues in controls and in Group II were 
44.15 ± 15.801 and 41.08 ± 15.774, respectively. Whereas the per-
centage of new connective tissue in Group I was 47.91 ± 19.623, 
the percentages of new connective tissues in Groups III, IV and V 
were 26.69 ± 21.620, 8.16 ± 10.746 and 7.89 ± 6.492, respectively. 
Safety assessed by mortality, clinical signs, food and water 
consumption  
All follow-up animals survived for the duration of the study. In 
addition, no adverse clinical signs or symptoms were observed 
during the experimental period except in the two animals that 
showed ataxia and dysplasia of femurs mentioned above. There 
were no significant differences in food and water consumption 
between control and treated groups (data not shown).
Safety assessed by changes in body weight and hematology
No significant differences in body weights between controls and 
treated groups were observed during the study period (Fig. 6). 
No significant differences in hematological parameters were 
detected (Table 2); hemoglobin, hematocrit, total erythrocyte 
count, erythrocyte indices (MCV, MCH and MCHC), total leu-
kocyte count, differential leukocyte count, platelet and coagula-
tion time (PT, APTT) were similar across all groups.
Safety assessed by serum biochemistry 
Significant increases of BUN and calcium, and significant de-
creases of phosphorus were observed Group V compared to 
the control (P < 0.05). Significant decreases of chlorine and so-
dium were observed in Group III compared to the control (P < 
0.05). However, these differences were considered to be mini-
mal or within normal physiologic limits and not of biologic sig-
Table 2. Hematologic values in nude rats treated with hATMSC-loaded HA/TCP scaffolds
Group
items
Control Group I Group II Group III Group IV Group V
Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No.
Leukocytes (10
3/µL)   7.51 ± 2.063  10 7.61 ± 3.393  10 7.44 ± 2.650  10 7.04 ± 1.937  9 7.79 ± 3.330  9 7.71 ± 5.976  10
Erythrocytes (10
6/µL)   8.07 ± 0.286  10 7.83 ± 0.841  10 8.17 ± 0.545  10 8.08 ± 0.362  9 7.74 ± 1.076  9 8.06 ± 0.528  10
Hemoglobin (g/dL)   15.0 ± 0.84  10 14.7 ± 1.80  10 15.6 ± 1.11  10 15.4 ± 0.69  9 15.5 ± 1.02  9 15.2 ± 1.19  10
Hematocrit (%)   37.0 ± 1.87  10 36.5 ± 4.72  10 37.4 ± 2.62  10 36.8 ± 1.30  9 36.2 ± 3.42  9 37.6 ± 2.61  10
Platelets (10
3/µL) 1,008 ± 182.2  10 883 ± 311.2  10 994 ± 82.1  10 925 ± 242.5  9 964 ± 259.9  9 984 ± 406.1  10
RBC index
   MCV (fl)
   MCH (pg)
   MCHC (g/dL)
 
  45.8 ± 1.34 
  18.5 ± 0.66
  40.4 ± 1.68 
 
10 
10
10
   
46.5 ± 1.87 
18.8 ± 0.67 
40.4 ± 1.87 
 
10 
10
10
   
45.8 ± 1.40 
19.1 ± 0.62 
41.6 ± 0.78 
 
10 
10
10
   
45.6 ± 1.02 
19.1 ± 0.33 
41.9 ± 0.86 
 
9
9
9
 
47.2 ± 3.67 
20.4 ± 3.99 
42.9 ± 4.40 
 
9
9
9
 
46.6 ± 1.41 
18.8 ± 0.87 
40.4 ± 0.96 
 
10
10
10
WBC Differential  
  Counting (%)
   Neutrophils (%)
   Eosinophils (%)
   Basophils (%)
   Lymphocytes (%)
   Monocytes (%)
 
  49.7 ± 9.79 
    0.6 ± 0.28 
    0.5 ± 0.06 
  38.5 ± 9.17 
    8.8 ± 0.86 
10
10
10
10
10
 
53.1 ± 5.40 
0.7 ± 0.68 
0.4 ± 0.13 
34.3 ± 5.38 
9.5 ± 1.41 
 
10
10
10
10
10
 
49.6 ± 8.92 
0.7 ± 0.64 
0.6 ± 0.21 
38.1 ± 8.01 
9.0 ± 1.17 
10
10
10
10
10
48.6 ± 9.31 
0.7 ± 0.61 
0.5 ± 0.15 
39.9 ± 9.05 
8.5 ± 1.07 
9
9
9
9
9
47.8 ± 10.08 
0.7 ± 0.39 
0.5 ± 0.21 
39.7 ± 8.85 
9.2 ± 1.41 
9
9
9
9
9
43.8 ± 15.09 
0.5 ± 0.38 
0.5 ± 0.14 
44.5 ± 15.17 
8.6 ± 1.98 
10
10
10
10
10
Coagulation
   PT (time)
   APTT (time)
 
  16.9 ± 1.12 
  23.4 ± 8.81 
 
10
10
 
15.8 ± 1.62 
22.4 ± 4.24 
 
10
10
 
15.8 ± 1.46 
24.1 ± 4.95 
 
10
10
 
16.6 ± 1.90 
26.8 ± 6.73 
 
9
9
 
16.6 ± 1.63 
24.6 ± 1.75 
 
9
9
 
16.2 ± 1.51 
26.3 ± 2.31 
 
10
10
SD, standard deviation; RBC, red blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; WBC, 
white blood cell; PT, prothrombin time; APTT, activated partial thromboplastin time.Choi HJ, et al.  •  Efficacy and Safety of hATMSCs in Bone Defects
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nificance (Table 3).
Safety assessed by ophthalmologic examination and 
urinalysis
No visible evidence of ocular abnormalities of effects was detect-
ed in ophthalmologic examinations. There were no significant 
differences in the results of urinalysis between control and treat-
ed groups (data not shown). 
Safety assessed by ophthalmologic organ weights, necropsy 
findings and histopathological findings
There were no significant differences in the absolute and rela-
tive weights of major organs related to detoxification and excre-
tion (liver and kidney), immunity (spleen and thymus), endo-
crine function (adrenal glands and pituitary gland), circulation 
(heart), respiration (lung), nervous system (brain) or reproduc-
tion (testis) (data not shown) across groups. Results of gross post-
mortem examinations performed on all animals did not reveal 
any evidence of visible morphologic abnormalities in any ani-
mals used in the study. Histopathologic evaluations showed 
that the T-cell-dependent regions of thymus, spleen and lymph 
nodes were reduced or absent of, that were of the lesions seen 
in the athymic nude rats. There were no indications of any mi-
croscopic abnormalities related to the implantations of hATM-
SCs and HA/TCP scaffolds (data not shown).  
 
DISCUSSION
The efficacy and safety of stem cell therapies must be established 
in appropriate animal models before clinical application in hu-
mans. These models should take into account properties inherent 
in the stem cell population as well as the expressions of these 
properties over time. When we evaluate the efficacy and safety 
of human cells in laboratory animals, we should consider the im-
mune reactions between human cells and host animals. Where-
as in autografts and allografts human patients receive human 
cells in clinical studies of cell therapies, in preclinical studies of 
cell therapies laboratory animals typically receive human cells, 
or xenografts. Therefore, immune deficient animals have been 
widely used in stem cell research for several years (15, 16). 
  An appropriate testing system has not yet been established for 
the development of cell therapy for bone repair. We therefore 
conducted the present hybrid study of the efficacy and general 
toxicity of hATMSCs and HA/TCP scaffolds in an athymic nude 
rat bone defect models. We expect that the present study will 
support the establishment of a preclinical assessment system 
for MSCs as cell therapies by confirming the toxicity and regen-
eration of bone in an animal model. 
  Testing for general toxicity using appropriate models can help 
to define risks of adverse events and to design clinical monitor-
ing protocols with clear endpoints. The tumorigenic potential 
of MSCs presents a critical preclinical safety parameter. The same 
potential for self-renewal that makes stem cell therapy plausible 
may also promote cancer (17). Tasso et al. (10) observed sarco-
mas in mice implanted with MSCs/bioscaffolds that originated 
from the recipient’s tissues, which are widely used in tissue en-
gineering approaches. Although many authors describe MSCs 
as immunologically privileged (18, 19), it is critical to confirm 
Table 3. Serum biochemical values in nude rats treated with hATMSC-loaded HA/TCP scaffolds
Group
items
Control Group I Group II Group III Group IV Group V
Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No.
Urea Nitrogen (mg/dL) 17 ± 1.5  10 19 ± 3.9  10 18 ±2.6  10 18 ± 1.5  9 18 ± 1.9  9 22* ± 6.2  10
Cholesterol (mg/dL) 66 ± 14.5  10 60 ± 12.1  10 69 ± 12.9  10 67 ± 10.3  9 68 ± 14.1  9 68 ± 8.0  10
Total Protein (g/dL) 5.2 ± 0.28  10 5.0 ± 0.46  10 5.3 ± 0.33  10 5 ± 0.3  9 5.2 ± 0.27  9 5.1 ± 0.43  10
Albumin (g/dL) 1.9 ± 0.15  10 1.9 ± 0.15  10 2.0 ± 0.17  10 2 ± 0.1  9 1.9 ± 0.13  9 1.9 ± 0.21  10
Total Bilirubin (mg/dL) 0.0 ± 0.03  10 0.0 ± 0.03  10 0.0 ± 0.03  10 0 ± 0.0  9 0.0 ± 0.00  9 0.0 ± 0.00  10
AlkalinePhosphatase  
   (IU/L)
98 ± 22.2  10 140 ± 109.4  10 102 ± 19.1  10 87 ± 11.8  9 105 ± 24.1  9 110 ± 57.8  10
Aspartate Aminotransferase   
   (IU/L)
63 ± 12.1  10 83 ± 62.3  10 66 ± 16.4  10 65 ± 6.1  9 68 ± 15.0  9 82 ± 37.2  10
Alanine Aminotransferase 
   (IU/L)
26 ± 4.0  10 31 ± 6.7  10 28 ± 3.9  10 30 ± 4.0  9 35 ± 12.7  9 33 ± 9.4  10
Creatinine (mg/dL) 0.5 ± 0.05  10 0.6 ± 0.05  10 0.5 ± 0.07  10 1 ± 0.1  9 0.5 ± 0.07  9 0.5 ± 0.10  10
Triglycerides (mg/dL) 26 ± 12.5  10 17 ± 5.6  10 27 ± 10.3  10 25 ± 11.3  9 30 ± 22.2  9 25 ± 11.9  10
Glucose (mg/L) 145 ± 18.5  10 156 ± 74.0  10 142 ± 18.9  10 162 ± 28.3  9 160 ± 29.4  9 151 ± 32.2 10
A/G ratio 1 ± 0.1  10 1 ± 0.1  10 1 ± 0.1  10 1 ± 0.1  9 1 ± 0.1  9 1 ± 0.1  10
Potassium (mM/L) 4 ± 0.3  10 5 ± 0.3  10 5 ± 0.2  10 5 ± 0.2  9 5 ± 0.3  9 5 ± 0.8  10
Chlorine (mM/L) 105 ± 1.4  10 104 ± 3.2  10 105 ± 1.5  10 101* ± 1.8  9 104 ± 1.0  9 103 ± 1.8  10
Calcium (mg/dL) 8.9 ± 0.38  10 8.8 ± 0.45  10 9.0 ± 0.33  10 9 ± 0.3  9 9.2 ± 0.40  9 9.4* ± 0.44  10
Phosphorus (mg/dL) 6 ± 0.6  10 6 ± 0.3  10 6 ± 0.6  10 6 ± 0.5  9 6 ± 0.5  9 7* ± 1.7  10
Sodium (mM/L) 144 ± 1.3  10 144 ± 3.2  10 144 ± 1.8  10 141* ± 2.0  9 143 ± 1.0  9 144 ± 2.7  10
*Significantly different from the control group; P < 0.05. SD, standard deviation; hATMSCs, human adipose tissue-derived mesenchymal stem cells; HA/TCP, hydroxyapatite/
tricalcium phosphate. Choi HJ, et al.  •  Efficacy and Safety of hATMSCs in Bone Defects
490   http://jkms.org DOI: 10.3346/jkms.2011.26.4.482
that MSCs do not elicit immune responses in animal models. To 
evaluate the potential for immunological rejection and toxicity 
in the present study, we performed regular blood analyses; and 
for the same reason, our histological analyses centered on signs 
of immunological rejection. The methods used in this study may 
serve to guide the safety assessment of new cell therapies for 
orthopedics. We recommend the OECD Guidelines for Testing 
of Chemicals (TG409) for safety assessment of cell therapy, with 
some modifications. These protocols include 1) behavioral ob-
servations, general clinical signs, mortality, body weight and 
food consumption (the most general indicators of animal health 
status); 2) hematological and biochemical analysis; 3) urinaly-
sis; 4) ocular observations; 5) necropsy (organ weights, gross 
examination, histopathological examination); and 6) tumorige-
nicity (immunodeficient athymic nude rats). 
  The results of the present safety study indicate that transplan-
tation of hATMSCs with HA/TCP scaffolds into femoral segmen-
tal defects is safe without any detectable side effects, or local or 
systemic rejection. We found no evidence for ectopic tissue for-
mation in histopathological analysis. In an unpublished previous 
study of tumorigenicity in immunodeficient mouse strains, we 
observed that hATMSCs also do not form tumors in nude mice. 
  Concerns regarding bioscaffolds, which serve to retain cells 
at implant sites, include biocompatibility and susceptibility to 
degradation without inducing inflammation. In Group II, hAT-
MSCs alone were transplanted into the defect area. These ani-
mals showed little bone formation, because cells could not ad-
here and then were washed out, demonstrating the necessity of 
scaffolds in this setting. In orthopedics and traumatology a va-
riety of biomaterials have been developed and widely applied in 
bone defect management and skeletal tissue engineering, with 
satisfactory clinical outcomes (20). The HA/TCP scaffold that 
we used in this study consisted of an optimum balance of 60% 
HA and 40% TCP, because this composition was previously ob-
served to provide optimum performance in terms of controlled 
resorption and osseous substitution (21, 22). HA and TCP are 
osteoconductive, porous biomaterials that have similar compo-
sitions, structures, and characteristics to native bone with good 
biocompatibility (5). 
  We measured bone regeneration both qualitatively and quan-
titatively using radiographs, micro-CT and histology for efficacy 
assessment. In this study, HA/TCP alone did not lead to healing 
of segmental bone defects. Histological and radiographic anal-
yses revealed no fusion in any cases treated with HA/TCP alone, 
and that the tissues around the scaffolds were predominantly 
filled with fibrous tissue even at 16 weeks after treatment. A larg-
er amount of residual HA/TCP scaffolds were still visible in Group 
I than the hATMSCs-loaded scaffolds in Groups III, IV, and V. 
However, when HA/TCP scaffolds were loaded with hATMSCs, 
the transplanted cells stimulated more new bone formation as 
they were resorbed. In terms of cell loading density on HA/TCP, 
we found that the amounts of new bone formation and the re-
sorption of scaffolds increased with increased cell volumes. This 
suggests that the new bone formed in a cell loading density-de-
pendent manner, and that greater amounts of loading cells on 
HA/TCP scaffolds were beneficial for regenerating new bone. 
These data support the utility of HA/TCP scaffolds as cell-load-
ing carriers in stem cell therapy.
  There are several limitations of this study. First, the bone de-
fect model may need to be longer than 5 mm, because callus 
could be formed spontaneously along the plate. Callus forma-
tion was observed along the fixation plate in some samples, as 
was an occasional eccentric spicule of bone, usually present 
along the medial aspect of the femur. Second, further studies 
should conduct mechanical testing such as torsional stiffness 
and maximum torque. We did not perform such analyses due 
to the lack of necessary equipment and the need for samples for 
toxicity study. Further investigations should test this tissue-en-
gineering method in larger animals, before clinical trials in hu-
mans. It may also be useful to implement cell tagging techniques 
to monitor the journeys of transplanted cells in vivo (23-26).
  In conclusion, our data support the safety of hATMSCs and 
their potential for osteogenesis when used with HA/TCP scaf-
folds in a bone defect model using athymic nude rats. The scaf-
fold used in the present study, HA/TCP, is identified as a prom-
ising candidate for bone tissue engineering with hATMSCs. The 
preclinical efficacy and safety testing performed in this study 
provides a framework for standardization and implementation 
of regulatory requirements for emerging stem cell therapies in 
orthopedics.
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The purpose of this study was to establish a preclinical assessment system to evaluate the efficacy and safety of cell therapies in a 
nude rat bone defect model. Segmental defects (5 mm) were created in the femoral diaphyses and transplanted with medium, 
hydroxyapatite/tricalcium phosphate scaffolds (HA/TCP), hATMSCs, or three cell-loading density of hATMSC-loaded HA/TCP. Healing 
response was evaluated by serial radiography, micro-computed tomography and histology at 16 weeks. To address safety-concerns, 
we conducted a GLP-compliant toxicity study. SEM studies showed that hATMSCs filled the pores/surfaces of scaffolds in a cell-
loading density-dependent manner. We detected significant increases in bone formation in the hATMSC-loaded HA/TCP groups 
compared with other groups. The amount of new bone formation increased with increases in loaded cell number. No significant 
hATMSC-related changes were found in a toxicity study. In conclusion, hATMSCs loaded on HA/TCP enhance the repair of bone.